following I've early Good the my his and prior you XXXX the for CFO Leigh. this in STRATA financial October, was you, afternoon, Financial thank the Officer, to with like everyone, to lead and Thank and for call closely to work I'd quarter call. who promoted our had company of ability welcoming start have our confidence new in Chief by us department. to our Hill. Chris Lesovitz, Matt July afternoon joining opportunity in departure joined earnings Chris in third complete
increased results, quarter see and the levels quarter over in quarter the and third highlights. revenues revenue encouraged were third financial a starting third pre-COVID sequentially. our revenues with XXXX, the the to in XX% XXXX. XX% quarter also to Now quarter few in exceed sequentially. comparable increased X% Recurring We Total X% year-over-year of of
at the this year, the the dermatology due revenue execution in of seeing and XTRAC our up continued to the to results This commercial the the including XX are from utilization units initiatives in operational with of we've we XXX offices identified recovery of strong towards are XXX base recurring revenue drives levels, and devices, earlier installed each with total is end primarily XXX shift XX international improved June. XXX of Our quarter on third the and pre-COVID model. that exited internationally U.S. We recurring placements. U.S.
pleased growth partner continued obviously see abroad. We are of to the our footprint and here
As we pandemic third the we position in onset with time strongest the in third of the quarter to row. the our offices noted a ended for since of quarter last patient at dermatologist call, the visits the increasing
our trend these staffing that regions right we XTRAC This was placements as position interest While mechanisms was with remain already believe today, this larger in challenges, normalized rate. metropolitan prevalent to majority a our shortages especially in when group grow encouraging, some in are pandemic in staffing, our installed once Delta practices. in where returns confident some began see again the in variant. marketplace. especially again, spiked the in regions we a business. mid-quarter of the of Despite resurface strong, the new we to at seeing place have faster base we once our We more to and Ultimately, the are pattern, that
Ra derm Medicals Now our to the of on business. update an acquisition
customers made Ra already our recurring revenue have to and current in transitioning system headway significant model. We XTRAC
continue acquisition quarter. with with X in to third XXX first Thus weeks by quarter progress initial Pharos customers This Ra's the expect to into accretive field to placements from Pharos We customers be the in of closing, first comeback following fourth the to XXXX. far, did end meetings XX quarter review continued this conducted options. EBITDA we've
that XTRAC we We to an our revenue migration opportunities expand comeback and result QX expect representing Pharos reach. throughout in and will customer building opportunity pipeline tremendous a are further to into exciting of XXXX,
commercial Turning execution to our initiatives.
Business business a that and centralizing include overview identifying new recently delivering are great of the finish expansion. Director progress XXXX. sources, is an and well-positioned believe for of strong to We opportunities digit data analytics, a targeting, responsibilities all double for whose XXXX We and making in Operations STRATA added growth
levels. and positive above year per and from usage entered execution for previous our historically impact continue have as increase investment in revenues. sequential QX, above QX a which remain to Our the system patients and and new in metric requests of approximately high-volume The $X.X to in patients. a in driving These insurance consumer increase all $XX,XXX see XTRAC which accounts of accounts that XXXX number growth our XXX increased force, over recurring potential contributed throughout continues the as accounted revenues the defined for customers XX% the High high-volume with focus in represents who and customers. that a benefit quarter, year, XX.X% demonstrated sales focus existing has of and levels. track. the in into reflects RDX been volume produce our expanding at calendar in the RDX XXXX XXX, trend in charts direct patients recurring marketing to are have on customers business, DTC key we revenues million we to charts, marketing and continued and revenue
we non-revenue and of that we and reduced closed the for of more this XXX. been QX, metric online debt severely at by year are than key the to yet end XXX many a a By end to January year. Another impacted XXXX Bringing had regenerating We X, reduced further but devices, XX. pandemic not has that started with QX, producing priority started number by track these customers customers back XTRAC these XXXX the revenues. accounts of
the devices average start-up throughout with days. the of new been U.S. total While XX% of added generating is installed of have time XX percentage below systems an our total to year, non-revenue non-revenue generating goal our keep base
initiative dermatology marketing direct our continues to Lastly, take shape. new
selling services with the highlight of further sales laser benefits support and be will features force the We that provide. and providing updated materials XTRAC the the we
vitiligo for for a We the of exciting in payers a with XXXX. indication, third-party the which discussed an company in opportunity work the with continue to improving goal past with vendor coverage have interact we to is
We research are will gather going with office-based more feedback help further and that our interacting fine-tune dermatologists forward. messaging directly KOLs to and
dermatologist driver business for a we as to indications. key expect be We all marketing the expanded in seek to to XXXX usage across continue direct
to international Turning business. our
Outside particularly placed of over laser revenue quarter the The our vitiligo During important all X United total increase opportunity which the These of XXX% XX, the element under overall we goals is potential, model. OUS the remains our recurring growth a XXXX, brings excimer for XXXX. with States, an third placements indication units in will In additional to business into the our for requires protocol progress steps in beyond. than pleased to our to with year vitiligo XXXX we more as taking a pre-COVID levels further grow treatment markets. am business this back opportunity be This the and building I psoriasis. as far expand additional important summary, so vitiligo in X treatments focus and
investment our installed and who ramped We additional on Ra are and up options excimer acquisition The in new over sales of use gives base. have sold customers XXX growing to our now going us on and limited while focused the lasers usage force have potential placements forward. sales adding marketing
our base recurring to accounts continue to to XTRAC the model, growing these more We of expect further revenues. move and
which we international in to in our further to targeted reach. expand continues additional markets Our business have and grow, XXXX
and actively more to and the sell are looking complementary M&A we products. Lastly, through to into utilize expansion engage ability ways force our sales opportunities additional fully
confident stated are recurring As the we before, have levels of the we year. can XXXX end revenue return we by to
improved our equipment our the lead revenue and this for installed our the Chris? will call value shareholders. to we of We recurring base to model turn Chris sustainable to CFO, expect sales more confident our Lesovitz. will that, as decline slightly I With to model, move are over but
